+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Depression Therapy & Treatment Market Insights, Opportunity Analysis, Market Shares and Forecast 2017 - 2023

  • ID: 3050457
  • Report
  • Region: Global
  • 149 pages
  • Occams Business Research and Consulting
1 of 3


  • Abbot Laboratories
  • Brainsway
  • Fisher Wallace
  • GlaxoSmithKline
  • MagVentures
  • Merck Sharp &Dohme
  • MORE
Depression treatment market is segmented on the basis of antidepressants drugs, devices and therapies. Antidepressants are the largest market segment. Antidepressants are the most popular treatment methods. Every year more than five billion prescriptions are written globally. Antidepressants segment consists of big pharmaceuticals companies like Eli Lily, Pfizer, GlaxoSmithKline and Forest Laboratories. All these companies are branded drug manufacturers. Some of the popular drugs produced by these companies are Cymbalta (Eli Lily) and Effexor and Pristiq (Pfizer). The devices market is the fastest growing market segment.

1. Pfizer
2. GlaxoSmithKline
3. Forest Laboratories
4. Abbot Laboratories
5. Eli Lilly and Company
6. Merck Sharp &Dohme
7. Sanofi
8. Teva Pharmaceuticals Industries
9. Mayo Clinic
10. Sun Pharmaceuticals
11. Brainsway
12. Fisher Wallace
13. MagVentures
14. Lundbeck
15. BoehringerIngelheim GmbH
16. Roche Holding AG

This Research Report covers
1. Historical data
2. Revenue forecasts, growth rates and CAGR upto 2022
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data
6. Deep profiles top competitive companies

Please allow up to 72 hours for delivery.
Note: Product cover images may vary from those shown
2 of 3


  • Abbot Laboratories
  • Brainsway
  • Fisher Wallace
  • GlaxoSmithKline
  • MagVentures
  • Merck Sharp &Dohme
  • MORE
Chap 1. Executive Summary
1.1. Depression therapy, device and drugs market
1.2. Methodology For Market Estimation
Chap 2. Market Overview –Depression Is A Major Concern Worldwide
2.1. Introduction
2.2. Depression is most common in 40-60 years of age group
2.3. Types of Depressions
2.3.1. Seasonal Affective Disorder (SAD)
2.3.2. Uni-polar or Major Depression
2.3.3. Dysthymia or Dysthymia Disorder
2.3.4. Postpartum Depression
2.3.5. Atypical Depression Psychotic Depression Bipolar Disorder
2.4. Value Chain Analysis
2.4.1. For Drugs Manufacturers Distributors Retailers End-Users
2.4.2. For Devices Manufacturers Distributors End-Users
2.5. Drivers
2.5.1. Growing acceptance of Depression in the developing nations
2.5.2. Increase in sales of antidepressants due to unhealthy life styles
2.6. Restraints
2.6.1. High price of Psycho therapy is a major restraint
2.6.2. Patents expiry is a major issue
2.6.3. Regulatory Compliance is important for the market to grow
2.7. Challenges
2.7.1. Generic Vs Branded – leads to price reduction
2.8. Opportunities
2.8.1. Significant Unmet Clinical needs has tremendous market potential
2.8.2. Decline in drug market offset bygrowing demand for personal therapies & devices
2.9. Key Findings
2.9.1. Negative Growth Rate in Antidepressants market
2.9.2. Rising acceptance for depression treatment in Asia Pacific
2.9.3. Market is shifting from branded to generic drugs
2.10. Strategic Recommendations
2.10.1. Market needs new anti depressant drugs
Chap 3. Market Segmentation
3.1. Antidepressants
3.2. Consumption of Antidepressants
3.2.1. Generic Drugs are preferred OVER Branded Antidepressants due to lower cost
3.3. Selective serotonin reuptake inhibitors (SSRIs)
3.3.1. Prozac (Fluoxetine)
3.3.2. Paroxetine (Paxil)
3.3.3. SERTRALINE (Zoloft)
3.3.4. Escitalopram oxalate (Lexapro)
3.3.5. Citalopram (Celexa)
3.3.6. Serotonin and norepinephrine reuptake inhibitors (SNRIs).
3.3.7. Duloxetine (Cymbalta)
3.3.8. Effexor
3.3.9. Norepinephrine and dopamine reuptake inhibitors (NDRIs)
3.4. Atypical antidepressants
3.4.1. Trazodone
3.4.2. Tricyclic antidepressants (TCA)
3.4.3. Tofranil (Imipramine)
3.4.4. Monoamine oxidase inhibitors (MAOIs) Tranylcypromine (Parnate)
3.4.5. Phenelzine (Nardil)
3.4.6. Other medications
3.5. Therapies
3.5.1. Cognitive Behavior Therapy (CBT)
3.5.2. Electroconvulsive Therapy (ECT)
3.5.3. Rational emotive behavior therapy (REBT)
3.5.4. Device enabled therapies Transcranial Magnetic Stimulation (TMS) therapy Deep Brain Stimulation Vagus Nerve Stimulator Virtual Reality (VR) Smart phone applications
3.5.5. Other Therapies Ketamine therapy
3.5.6. Special Conditions Antidepressants discontinuation syndrome (ADS) Treatment-resistant depression Rehabilitation centre for depression Rehabilitation programs through VR technology
Chap 4. Depression Prevalence by Gender
4.1. Depression in Men
4.2. Depression in Women
4.2.1. Depression in Elderly is a common phenomenon
Chap 5. Resurgent Generic Drugs market due to patent expiry
Chap 6. Competitive Trends, Strategies & Market Share
6.1. Key Focus on Cost Control Impacting R&D Initiatives
6.2. Partnerships and acquisitions
6.3. Generic drug manufacturers focusing on patent expiration and semi regulated markets
6.4. Market Share Analysis
Chap 7. Geographical analysis
7.1. Devices market is growing in North America, Europe and Asia Pacific
7.2. North America is the highest drug market for depression
7.2.1. US has the largest patient pool for depression drugs & devices
7.2.2. US market is driven by strict regulations
7.2.3. Mental illness is a major disease in Canada
7.3. Depression is a major concern in Europe
7.3.1. almost 16.7 million people suffer from depression in the UK
7.3.2. Regulations in the United Kingdom
7.3.3. France has the highest rate of depression amongst developed nations
7.3.4. Germany has prevalence rate of 4.5-5% for depression
7.3.5. Spain has strict regulations for depression drugs
7.4. Asia Pacific has a strongly emerging generic drugs market
7.4.1. Approx 60% of the population in China is undiagnosed for depression
7.4.2. India has over 10 million people suffering from depression
7.4.3. Financial burden of depression in Japan amounts to nearly $15 billion
7.4.4. Depression is a common occurring health issue in the age group 12-25 years in Australia
Chap 8. Corporate profiling
8.1. Pfizer
8.1.1. Overview
8.1.2. Strategic Analysis
8.1.3. SCOT Analysis
8.2. GlaxoSmithKline
8.2.1. Overview
8.2.2. SCOT Analysis
8.3. Forest Laboratories
8.3.1. Overview
8.3.2. SCOT Analysis
8.4. Abbot Laboratories
8.4.1. Overview
8.4.2. SCOT Analysis
8.5. Eli Lilly and Company
8.5.1. Overview
8.5.2. SCOT Analysis
8.6. Merck Sharp &Dohme
8.6.1. Overview
8.6.2. SCOT Analysis
8.7. Sanofi
8.7.1. Overview
8.7.2. SCOT Analysis
8.8. Neuronetics
8.8.1. Overview
8.8.2. SCOT Analysis
8.9. Teva pharmaceuticals Industries
8.9.1. Overview
8.9.2. SCOT Analysis
8.10. Mayo Clinic
8.10.1. Overview
8.10.2. Mayo Clinic product portfolio in depression therapy
8.10.3. SCOT Analysis
8.11. Sun Pharmaceuticals
8.11.1. Overview
8.11.2. SCOT Analysis
8.12. Brainsway
8.12.1. Overview
8.12.2. SCOT Analysis
8.13. Fisher Wallace
8.13.1. Overview
8.13.2. SCOT Analysis
8.14. MagVentures
8.14.1. Overview
8.15. Lundbeck
8.15.1. Overview
8.15.2. Strategic moves
8.15.3. SCOT Analysis
8.16. BoehringerIngelheim GmbH
8.16.1. Overview
8.16.2. SCOT Analysis
8.17. Roche Holding AG
8.17.1. Overview
8.17.2. Strategic Moves
8.17.3. SCOT Analysis
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Forest Laboratories
Abbot Laboratories
Eli Lilly and Company
Merck Sharp &Dohme
Teva Pharmaceuticals Industries
Mayo Clinic
Sun Pharmaceuticals
Fisher Wallace
BoehringerIngelheim GmbH
Roche Holding AG
Note: Product cover images may vary from those shown